Republican senators from Minnesota unveiled a bill Sept. 19 that would require drugmakers to provide free insulin to eligible patients for up to a year, according to the Pioneer Press.

In its Drug Pipeline Insights report for the third quarter, OptumRx highlights five drugs under FDA review that may soon make waves in the healthcare industry for clinical quality, effectiveness and cost. They are listed below:

Novartis said the death of an infant this year in a clinical trial testing its gene therapy Zolgensma was not caused by a toxic drug reaction, according to EndPoints News.

A medication safety expert filed a petition with the FDA asking it to further regulate a commonly prescribed antibiotic because it increases the risk of suicide, according to ABC Action News.

The former CEO of drug compounding company Pharmakon Pharmaceuticals was sentenced Sept.18 to nearly three years in prison for conspiracy and adulterating drugs, according to the Indianapolis Star.

Hospitals earn a greater profit from physician-administered drugs than pharmaceutical manufacturers themselves, according to a recent analysis by the Partnership for Health Analytic Research.

The American Clinical Laboratory Association sent a letter to the FDA Sept. 18 calling the agency's recent regulations on reporting genetic testing results to patients "inappropriate" and "troubling."

A former compliance officer at McKesson is under criminal investigation for allegedly conspiring to illegally distribute narcotics, according to The Washington Post.

Walgreens agreed Sept. 17 to settle a class-action lawsuit alleging it violated antitrust laws by restricting search advertisements, according to Digital News Daily.

Sandoz, the generic arm of Novartis, is stopping worldwide distribution of its heartburn medicine that contains high levels of a cancer-causing impurity, according to STAT.